Organon & Co (MIL:1OGN)
€ 14.35 0 (0%) Market Cap: 3.72 Bil Enterprise Value: 11.38 Bil PE Ratio: 2.99 PB Ratio: 7.87 GF Score: 45/100

Organon & Co at Piper Sandler Healthcare Conference Transcript

Nov 29, 2022 / 02:00PM GMT
David A. Amsellem
Piper Sandler & Co., Research Division - MD & Senior Research Analyst

Okay. Good morning. Welcome to the 34th Annual Piper Sandler Healthcare Conference. I'm David Amsellem from the specialty pharma team, Eric Piper. Our next company, fireside chat is Organon and we're delighted to have Kevin Ali, CEO and Matt Walsh, CFO. Thanks so much for joining us and lots to talk about. So, let's just dive right in if that's okay.

Kevin Ali
Organon & Co. - CEO & Director

Sure.

Questions & Answers

David A. Amsellem
Piper Sandler & Co., Research Division - MD & Senior Research Analyst

So, I like to start off with a couple of high level questions. And the first is, as we move into '23 -- and I know you get this a lot, what are your biggest priorities in terms of BD M&A? More specifically, is the goal to bolster the pipeline or a commercial stage assets or mix of both?

And the reason I started there is, I guess, it's something that you've talked about a lot on in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot